STAGE IIIC NON-SMALL CELL LUNG CANCER
Clinical trials for STAGE IIIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for STAGE IIIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets hard-to-treat lung cancer in early trial
Disease control CompletedThis early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutant non-small cell lung cancer that could not be treated with radiation. The main goal was to check safety and find the right dose. …
Matched conditions: STAGE IIIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 10:20 UTC
-
New combo therapy for advanced lung cancer shows promise in early trial
Disease control CompletedThis study tested a new treatment approach for people with advanced non-small cell lung cancer that cannot be removed with surgery. The treatment combined MRI-guided radiation, chemotherapy, and an immunotherapy drug called durvalumab. The goal was to see if this approach is safe…
Matched conditions: STAGE IIIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 10:07 UTC